Core Viewpoint - Jiangsu Kangyuan Pharmaceutical Co., Ltd. has received the drug registration certificate for "Canpu Granules" from the National Medical Products Administration, marking a significant advancement in the treatment options for pelvic inflammatory disease (PID) and its sequelae [1][2]. Company Summary - "Canpu Granules" is an exclusive product developed based on clinical experience from Professor Tan Yong of Nanjing University of Chinese Medicine, integrating traditional Chinese medicine principles [1]. - The clinical studies indicate that "Canpu Granules" significantly alleviates chronic pelvic pain associated with PID, showing improved efficacy over time and demonstrating good safety and tolerability [1]. - The company has invested approximately 62.16 million yuan in the research and development of "Canpu Granules" [2]. Industry Summary - PID is a common condition among women in China, with about 41% of reproductive-age women experiencing varying degrees of gynecological inflammatory diseases, and the incidence rate among married women reaching 70% [2]. - Approximately 25% of PID patients may suffer from sequelae, which complicates treatment due to long-term inflammation and the difficulty of anti-inflammatory drugs reaching the affected areas [2]. - The approval of "Canpu Granules" provides a new treatment option for patients suffering from PID sequelae, indicating a promising market outlook for this product [2].